Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Inclusion Criteria

• Men and women must be 18 years of age or older
• A current diagnosis of advanced, unresectable GEP-NET
• Provided written informed consent to participate in the study
• Currently receiving lanreotide or octreotide LAR and has received at least one prior injection of current somatostatin analogues (SSA).

Exclusion Criteria

• Receiving treatment with lanreotide or octreotide LAR as part of a clinical trial
• Scheduled to receive a dose of lanreotide or octreotide LAR that would necessitate more than 1 injection on the same day
• Scheduled to receive any other treatment in the infusion center/room on the same day and as part of the same appointment
• Known hypersensitivity to somatostatin analogues